Opportunities and challenges of immune checkpoint inhibitors for extensive‐stage small‐cell lung cancer
Abstract Small‐cell lung cancer (SCLC) accounts for 15%–20% of primary lung cancers, and it is characterized by low differentiation, rapid proliferation, and early metastasis. At least two‐thirds of SCLC patients present with the extensive stage (ES) at the time of initial clinical diagnosis. Over t...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-08-01
|
| Series: | Cancer Innovation |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cai2.23 |